GL GLP-1 drugs Loading... : Investor Sentiment and Bull/Bear Views

GLP-1 drugs show a large awareness-to-adoption gap: 90% of Americans have heard of them but only 11% use them, advertising is pervasive, adoption is spreading from celebrities and tech-centric markets into the mainstream, and the cultural shift toward thinness is being driven by this new technology. This creates a durable demand tailwind for the GLP-1 category, while safety and conversion remain key variables.

GLP-1 drugs are worth close to a trillion dollars and are effectively a consumer product rather than a disease treatment - the best thing since the iPhone - because users stop thinking about food and get their willpower back; he personally takes them. Their value comes from serving people who are not sick, which shows how much larger biotech's market becomes when it addresses consumer wellness (weight, sleep, muscle, feeling better) rather than only disease.

Nearly one in seven Americans take a GLP-1 and 20% have tried them. Adoption will rise, possibly over half of Americans, especially those with family obesity, often at lower doses via compounding/gray market. In theory, obesity could be eradicated.

GLP-1s are potentially very interesting technology and it makes sense to put many overweight or obese Americans on them to jumpstart health, but universal GLP-1s will not solve the chronic-disease crisis. If people keep eating poor-quality food while on GLP-1s, they risk protein and micronutrient deficiencies; the food system still must be fixed.

Speaking from his own experience going from 213 to 172 lbs on Ozempic after a doctor told him he was not diabetic but was fat, Calacanis calls GLP-1s a miracle drug that tens of millions of Americans have already tried and that is about to move to pill format. Because obesity drives the four horsemen (heart disease, kidney failure, liver disease and dementia) and GLP-1s appear to blunt all four, he argues the drugs should be made available to every American, which would massively widen the user base.

Doustdar says obesity is not one homogeneous condition but multiple diseases with different patient needs, and approximately 2 billion people have obesity. This large, heterogeneous, and underpenetrated market supports multiple GLP-1 treatment modalities and formats, including both injections and oral pills.

GLP-1 use will become ubiquitous, with oral Ozempic coming and 50 million Americans on these drugs within five years. Despite eventual backlash and micronutrient deficiency concerns, demand and efficacy make it a major trend he is bullish on.

Chamath makes a demand-side argument for GLP-1 adoption. The competing longevity protocols from Gary Brecka, Andrew Huberman and Brian Johnson are similar enough to be confusing and different enough to impose a real cognitive load on a busy person; he describes paying for doctors in two cities and a third party to reconcile them, and getting worse care for the money. GLP-1 drugs win because they collapse all of that into popping one pill that solves the underlying problem without requiring the patient to assemble a protocol, and an oral formulation is almost here. On that basis he expects these products to keep growing pretty dramatically.